Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function

Summary

Low-molecular-weight heparins (LMWHs) accumulate in patients with impaired renal function. As this accumulation depends on heparin chain length and subsequent reticulo-endothelial/renal elimination, LMWHs might have different pharmacodynamic profiles. The primary objective was to examine if any accumulation effect of two LMWHs, enoxaparin and tinzaparin, occurred after repeated administration of a prophylactic dose over eight days in elderly patients (age >75 years) with creatinine clearance between 20 and 50 ml/min and body weight <65Kg. Patients were openly randomized to two groups (enoxaparin 4,000 IU or tinzaparin 4,500 IU once daily). Anti-Xa was measured on day 1 and day 8. Blood samples were taken at 0, 2, 4, 5, 6, 9, 12, 16 and 24 hours. The primary end point was the accumulation factor calculated as a ratio between the maximal anti-Xa activity on day 1and day 8. Fifty-five patients were included (mean age 87.9 ± 5.5 ).The creatinine clearance was 34.7 ± 11.4 ml/min; the body weight was 52.3 ± 8.6 kg. The accumulation factor defined was not significant for tinzaparin (1.05, p=0.29) while it was significantly enhanced for enoxaparin (1.22, p <0.0001). In this pharmacodynamic study performed in elderly patients with impaired renal function, a statistically significant accumulation effect was observed after eight days of prophylactic treatment with enoxaparin but not with tinzaparin, which are two LMWHs with different chain lengths. Trials based on clinical end points should be conducted to evaluate the clinical relevance of these observations.

Keywords

LMWHs - thromboprophylaxis - elderly - renal insufficiency

• References

• 1 Samama MM, Cohen AT, Darmon JY, Desjardins L. et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999; 341: 793-800.
• 2 Leizorovicz A, Cohen AT, Turpie AG. et al. PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110: 874-879.
• 3 Mismetti P, Laporte-Simitsidis S, Tardy B. et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: A meta-analysis of randomised clinical trials. Thromb Haemost 2000; 83: 14-19.
• 4 Heit JA, Silverstein MD, Mohr DN. et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost 2001; 86: 452-463.
• 5 Stein PD, Hull RD, Kayali F. et al. Venous thromboembolism according to age: the impact of an aging population. Arch Intern Med 2004; 164: 2260-2265.
• 6 Silverstein MD, Heit JA, Mohr DN. et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158: 585-593.
• 7 Oger E for the EPI-GETBO study group. Incidence of venous thromboembolism: a community-based study in Western France. Thromb Haemost 2000; 83: 657-660.
• 8 Low-molecular-weight heparins and haemorrhagic risk. French Drug Agency (letter). Available at. http://www.agmed.sante.gouv.Fr
• 9 Lim W, Dentali F, Eikelboom JW. et al. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006; 144: 673-684.
• 10 Geerts WH, Pineo GF, Heit JA. et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (Suppl. 03) Suppl 338S-400S.
• 11 Samama MM. Contemporary laboratory monitoring of low molecular weight heparin. Clin Lab Med 1995; 15: 119-123.
• 12 Boneu B, de Moerloose P. How and when to monitor a patient treated with low molecular weight heparin. Sem Thromb Haemost 2001; 27: 519-522.
• 13 Mahé I, Drouet L, Chassany O. et al. Low molecular weight heparin for the prevention of deep venous thrombosis: a suitable monitoring in elderly patients?. Pathophysiol Haemost Thromb 2002; 32: 134-136.
• 14 Siguret V, Pautas E, Fevrier M. et al. Elderly patients treated with tinzaparin administratered once daily (175 anti-Xa IU/kg): anti Xa and anti IIa activities over 10 days. Thromb Haemost 2000; 84: 800-804.
• 15 Samama MM, Gerotziafas GT. Comparative pharmacokinetics of LMWHs. Sem Thromb Haemost 2000; 26: 31-38. (Suppl. 01) Supp
• 16 Planes A, Samama MM, Lensing AW. et al. Prevention of deep vein thrombosis after hip replacement--comparison between two low-molecular heparins, tinzaparin and enoxaparin. Thromb Haemost 1999; 81: 22-25.
• 17 Couturaud F, Lacut K, Leroyer C, Mottier D. Assessment of the risk and prophylactic treatment of venous thromboembolism in elderly. Pathophysiol Haemost Thromb 2004; 33: 362-365.
• 18 Alikhan R, Cohen AT, Combe S, at al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagul Fibrinolysis 2003; 14: 341-334.
• 19 Oger E, Bressollette E, Nonent M. et al. High prevalence of asymptomatic deep vein thrombosis on admission in a medical unit among elderly patients. Thromb Haemost 2002; 88: 592-597.
• 20 Leizorovicz A, Mismetti P. Preventing venous thromboembolism in medical patients. Circulation 2004; 110 (Suppl. 01) Suppl IV13-19.
• 21 Hulot JS, Montalescot G, Lechat P. et al. Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome. Clin Pharmacol Ther 2005; 77: 542-552.
• 22 Barrett JS, Gibiansky E, Hull RD. et al. Population pharmacokinetics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis. Int J Clin Pharmacol Ther 2001; 39: 431-446.
• 23 Mismetti P, Laporte-Simitsidis S, Navarro C. et al. Aging and venous thromboembolism influence the pharmacokinetics of the anti-factor Xa and antithrombin activities of a low molecular weight heparin (nadroparin). Thromb Haemost 1998; 79: 1162-1165.
• 24 Bruno R, Baille P, Retout S. et al. Population pharmacokinetics and pharmacokinetics of enoxaparin in unstable angina and non-ST-segment elevation myocardial infarction. Br J Clin Pharmacol 2003; 56: 407-414.
• 25 Pautas E, Gouin I, Bellot O. et al. Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients. Drug Saf 2002; 25: 725-733.
• 26 Hirsch J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 188S-203S. (Suppl. 03) Suppl
• 27 Desjardins L, Boutitie F, Samama MM. et al. Correlation of plasma coagulation parameters with thromboprophylaxis, patients characteristics, and outcome in the MEDENOX study. Arch Pathol Lab Med 2004; 128: 519-526.
• 28 Bara L, Boutitie F, Samama MM. et al. Occurrence of thrombosis and haemorrhage, relationship with anti- Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery. Br J Haematol 1999; 104: 230-40.
• 29 Mammen EF, Arcelus J, Messmore H. et al. Clinical differentiation of low molecular weight heparins Semin. Thromb Hemost 1999; 725 (Suppl. 03) Supple 135-144.
• 30 Collignon F, Frydman A, Caplain H. Comparison of pharmacokinetics profiles of 3 LMWH administered in healthy volunteers. Thromb Haemost 1995; 73: 630-640.
• 31 Erikson I B, Soderberg K, Widlung L. A comparative Study of 3 low molecular weight heparin in healthy volunteers. Thromb Haemost 1995; 73: 398-401.
• 32 Azizi M, Veissier-Belot C. Comparison of biological activities of 2 low molecular weight heparin. Br J Clin Pharmacol 1995; 40: 577-584.
• 33 Kitchen S, Lampietro R, Woolley AM. et al. Anti- Xa monitoring during treatment with low-molecular-weight- heparin or danaparoid: inter-assay variability. Thromb Haemost 1999; 82: 1289-1293.
• 34 Laposata M, Green D, Van Cott EM. et al. College of American Pathologists conference XXXI on laboratory montoring of low-molecular-weight-heparin, danaparoid, hirudin, and related compounds, and argatroban. Arch Pathol Lab Med 1998; 122: 799-807.
• 35 Sanderink GJ, Guimart CG, Ozoux ML. et al. Pharmacokinetics and pharmacokinetics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res 2002; 105: 225-231.